- Home
- ANNX vs DCTH Comparison
ANNX vs DCTH Comparison
Compare ANNX & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- DCTH
- Stock Information
- Founded
- ANNX 2011
- DCTH 1988
- Country
- ANNX United States
- DCTH United States
- Employees
- ANNX N/A
- DCTH N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- ANNX Health Care
- DCTH Health Care
- Exchange
- ANNX Nasdaq
- DCTH Nasdaq
- Market Cap
- ANNX 334.1M
- DCTH 388.3M
- IPO Year
- ANNX 2020
- DCTH N/A
- Fundamental
- Price
- ANNX $2.92
- DCTH $8.67
- Analyst Decision
- ANNX Strong Buy
- DCTH Strong Buy
- Analyst Count
- ANNX 4
- DCTH 5
- Target Price
- ANNX $13.00
- DCTH $22.60
- AVG Volume (30 Days)
- ANNX 1.9M
- DCTH 1.2M
- Earning Date
- ANNX 11-10-2025
- DCTH 11-04-2025
- Dividend Yield
- ANNX N/A
- DCTH N/A
- EPS Growth
- ANNX N/A
- DCTH N/A
- EPS
- ANNX N/A
- DCTH 0.03
- Revenue
- ANNX N/A
- DCTH $79,603,000.00
- Revenue This Year
- ANNX N/A
- DCTH $135.11
- Revenue Next Year
- ANNX N/A
- DCTH $36.30
- P/E Ratio
- ANNX N/A
- DCTH $248.94
- Revenue Growth
- ANNX N/A
- DCTH 251.54
- 52 Week Low
- ANNX $1.29
- DCTH $8.33
- 52 Week High
- ANNX $6.93
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- ANNX 45.55
- DCTH 31.43
- Support Level
- ANNX $2.66
- DCTH $8.39
- Resistance Level
- ANNX $3.03
- DCTH $8.82
- Average True Range (ATR)
- ANNX 0.24
- DCTH 0.50
- MACD
- ANNX -0.04
- DCTH -0.12
- Stochastic Oscillator
- ANNX 26.98
- DCTH 13.50
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.